Xeris Biopharma Holdings, Inc.
XERS · XNASCIK 1867096fmd_05KZDG0ZB229VZ7HDWTR3MW5YQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 20 | 50 | 110 | 164 | 203 | 292 |
| Research and development | 21 | 25 | 21 | 22 | 26 | 31 |
| Selling, general and administrative | 74 | 126 | 138 | 146 | 163 | 182 |
| Operating income | (84) | (115) | (82) | (44) | (34) | 25 |
| Interest expense | 11 | 7 | 14 | 27 | 30 | 29 |
| Other non-operating income (expense) | (8) | (8) | (14) | (19) | (23) | (24) |
| Income before taxes | – | (123) | (96) | (64) | (57) | 1 |
| Income tax expense | (0) | 0 | (1) | (1) | (2) | 0 |
| Net income from continuing operations | – | (123) | (95) | (62) | (55) | 1 |
| Net income | (91) | (123) | (95) | (62) | (55) | 1 |
| Net income to common shareholders | – | – | – | (62) | (55) | 1 |